Company / Capital Expenditures
C4 Therapeutics, Inc. Capital Expenditures History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$607.0K
FY2025
5-year range
$607.0K / $1.7M
FY2022-FY2025
Trend
-64.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $2M to $607,000 over the past 2 years.
Based on SEC 10-K filings.
$607,000 in FY2025 with a 3-year CAGR of -22.0%.
Declined from $2M to $607,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -22.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -22.0%, indicating a declining trend.
- In FY2025, capital expenditures decreased 64.5% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $607.0K | -64.5% |
| FY2024 | $1.7M | +0.0% |
| FY2023 | $1.7M | +33.8% |
| FY2022 | $1.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026